A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine

Published:2023-12-20 Issue:2 Volume:38 Page:263-265
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Ripamonti Diego¹,Rusconi Stefano²,Zazzi Maurizio³

Affiliation:

1. Infectious Diseases Unit, ASST Papa Giovanni XXIII, Bergamo

2. Infectious Diseases Unit, ASST Ovest Milanese, Legnano General Hospital and DIBIC ’Luigi, Sacco’, University of Milan, Milan

3. Department of Medical Biotechnology, University of Siena, Siena, Italy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference20 articles.

1. Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2 M);Chounta;Patient,2021

2. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries;Akinwunmi;Sex Transm Infect,2021

3. High acceptability and perceived feasibility of long-acting injectable antiretroviral treatment among people living with HIV who are viremic and health workers in Uganda;Kennedy;AIDS Patient Care STDS,2023

4. The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions;Rusconi;Int J Antimicrob Agents,2022

5. Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, noninferiority trial;Ramgopal;Lancet HIV,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3